Drug Trial Radar · NCT04563195
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 1, 2022
Primary completion
Dec 2023
Study completion Jan 2025
Sponsor
- Lead sponsor
- Matthew C. BakerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.
Conditions
- Primary Sjogren's Syndrome
Interventions
tibulizumab (LY3090106)Drug
subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- whole unstimulated sialometryTime frame: baseline
- whole unstimulated sialometryTime frame: week 12
- salivary gland ultrasoundTime frame: baseline
- salivary gland ultrasoundTime frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.